Search - tctmd.com

Displaying 541 - 560 of 655

Sort: Relevancy | Date

News Daily News

Patients with Cardiac Arrest Fare Poorly After PCI

April 17, 2014

News Daily News

El Antidiabético Aleglitazar No Logra Reducir los Resultados Isquémicos de Diabéticos con SCA de Reciente Aparición

L.A. McKeown

April 11, 2014

News Daily News

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

L.A. McKeown

April 11, 2014

News Daily News

Remote Postconditioning Fails to Reduce Myocardial Injury in Non-urgent PCI Patients

April 09, 2014

Presentation

Effect of Aleglitazar on Cardiovascular Outcomes after ACS in Patients with Type 2 Diabetes

Presenter: A. Michael Lincoff

April 04, 2014

News Daily News

Registro FAST-MI: La Fibrinolisis y la PCI, Primaria arrojan una Supervivencia Similar a los 5 Años en Pacientes STEMI

L.A. McKeown

April 03, 2014

News Daily News

FAST-MI Registry: Fibrinolysis, Primary PCI Yield Similar 5-Year Survival in STEMI Patients

L.A. McKeown

April 03, 2014

News Conference News ACC 2014

GIPS-III: Diabetes Drug Metformin Not Cardioprotective in Nondiabetic STEMI Patients After Primary PCI

Jason Kahn

March 31, 2014

News Conference News ACC 2014

High-sensitivity Troponin Testing May Prevent Unnecessary Admissions for Chest Pain

L.A. McKeown

March 30, 2014

News Daily News

Mortality Benefit with ACE Inhibitors in Nonobstructive CAD

L.A. McKeown

March 20, 2014

News Daily News

HORIZONS-AMI: Kidney Damage During Primary PCI Closely Tied to Prognosis

March 20, 2014

News Daily News

HORIZONS-AMI: El Daño Renal Durante una PCI Primaria está Estrechamente asociado al Pronóstico

March 20, 2014

News Daily News

Beneficio sobre la Mortalidad con Inhibidores de la ECA en la EAC No Obstructiva

L.A. McKeown

March 20, 2014

News Daily News

Ticagrelor Loading Dose May be Unnecessary for ACS Patients Previously on Clopidogrel

Caitlin E. Cox

January 29, 2014

News Conference News AHA 2013

Risk of Kidney Injury Not Affected by High-Potency Statin Regimen in ACS Patients

Yael L. Maxwell

November 20, 2013

News Conference News TCT 2013

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

October 30, 2013

News Daily News

高风险亚组从瑞舒伐他汀中获得肾脏保护

Caitlin E. Cox

October 11, 2013

News Daily News

Los Subgrupos de Alto Riesgo obtienen Protección Renal de la Rosuvastatina

Caitlin E. Cox

October 11, 2013

News Daily News

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Caitlin E. Cox

October 11, 2013

Presentation

PRATO-ACS: Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in ACS

Presenter: M. Leoncini

October 09, 2013

Advertisement

Patients with Cardiac Arrest Fare Poorly After PCI

El Antidiabético Aleglitazar No Logra Reducir los Resultados Isquémicos de Diabéticos con SCA de Reciente Aparición

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

Remote Postconditioning Fails to Reduce Myocardial Injury in Non-urgent PCI Patients

Effect of Aleglitazar on Cardiovascular Outcomes after ACS in Patients with Type 2 Diabetes

Registro FAST-MI: La Fibrinolisis y la PCI, Primaria arrojan una Supervivencia Similar a los 5 Años en Pacientes STEMI

FAST-MI Registry: Fibrinolysis, Primary PCI Yield Similar 5-Year Survival in STEMI Patients

GIPS-III: Diabetes Drug Metformin Not Cardioprotective in Nondiabetic STEMI Patients After Primary PCI

High-sensitivity Troponin Testing May Prevent Unnecessary Admissions for Chest Pain

Mortality Benefit with ACE Inhibitors in Nonobstructive CAD

HORIZONS-AMI: Kidney Damage During Primary PCI Closely Tied to Prognosis

HORIZONS-AMI: El Daño Renal Durante una PCI Primaria está Estrechamente asociado al Pronóstico

Beneficio sobre la Mortalidad con Inhibidores de la ECA en la EAC No Obstructiva

Ticagrelor Loading Dose May be Unnecessary for ACS Patients Previously on Clopidogrel

Risk of Kidney Injury Not Affected by High-Potency Statin Regimen in ACS Patients

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

高风险亚组从瑞舒伐他汀中获得肾脏保护

Los Subgrupos de Alto Riesgo obtienen Protección Renal de la Rosuvastatina

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

PRATO-ACS: Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content